DOCSLIB.ORG

Biological Agents and Pandemics: Review of the Literature and National Policies TE-31-09-207-EN-N

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biological Agents and Pandemics: Review of the Literature and National Policies TE-31-09-207-EN-N Biological agents and pandemics: review of the literature and national policies TE-31-09-207-EN-N Biological agents and pandemics: review of the literature and national policies BIOLOGICAL AGENTS AND PANDEMICS: REVIEW OF THE LITERATURE AND NATIONAL POLICIES EU-OSHA – European Agency for Safety and Health at Work 1 Biological agents and pandemics: review of the literature and national policies Authors: Project Manager: Joanna Kosk-Bienko and Elke Schneider, European Agency for Safety and Health at Work (EU-OSHA) Project Leader: Zofia Pawłowska, Centralny Instytut Ochrony Pracy - Państwowy Instytut Badawczy CIOP-PIB, Poland Correspondents and experts: A. Schieder, S. Kaluza, Bundesanstalt für Arbeitsschutz und Arbeitsmedizin (BAuA), Germany L. Zapor, M. Pęciłło, Centralny Instytut Ochrony Pracy - Państwowy Instytut Badawczy (CIOP-PIB), Poland H. Taskinen, T. Hannu, Tyoterveyslaitos Institutet for Arbetshygien (FIOH), Finland C. Lebacle, Institut National de Recherche et de Sécurité pour la prévention des accidents du travail et des maladies professionnelles (INRS), France M. Tejedor, A. Miron, A. Hernández, Instituto Nacional de Seguridad e Higiene en el trabajo (INSHT), Spain S. Van Herpe, W. De Craecker, Karen, Institut pour la Prévention et le bien-être au travail/Instituut voor Preventie en Welzijn op het Werk (PREVENT), Belgium This report was commissioned by the European Agency for Safety and Health at Work (EU-OSHA). Its contents, including any opinions and/or conclusions expressed, are those of the author(s) alone and do not necessarily reflect the views of EU-OSHA. Europe Direct is a service to help you find answers to your questions about the European Union Freephone number (*): 00 800 6 7 8 9 10 11 (*) Certain mobile telephone operators do not allow access to 00 800 numbers, or these calls may be billed. More information on the European Union is available on the Internet (http://europa.eu). Cataloguing data can be found on the cover of this publication. Luxembourg: Office for Official Publications of the European Communities, 2009 ISBN -13: 978-92-9191-272-8 DOI: 10.2802/14733 © European Agency for Safety and Health at Work, 2009 Reproduction is authorised provided the source is acknowledged. EU-OSHA – European Agency for Safety and Health at Work (EU-OSHA) 2 Biological agents and pandemics: review of the literature and national policies Table of Contents List of figures and tables:........................................................................................................................ 5 Executive summary ................................................................................................................................ 7 1. General Introduction ..................................................................................................................... 9 2. Aims of the work and methodology............................................................................................. 11 3. Prevalence of diseases caused by infectious biological agents and their occurrence in occupational setting .................................................................................................................... 13 3.1. Introduction ................................................................................................................................ 13 3.2. Blood borne pathogens............................................................................................................... 14 3.2.1. Basic characteristics ....................................................................................................... 14 3.2.2. Prevalence of diseases caused by blood borne pathogens ........................................... 14 3.2.3. Works/occupations at risk............................................................................................... 17 3.3. Viral Haemorrhagic Fevers........................................................................................................ 19 3.3.1. Basic characteristics ....................................................................................................... 19 3.3.2. Prevalence of viral haemorrhagic fevers ........................................................................ 20 3.3.3. Works/occupations at risk............................................................................................... 22 3.4. Q – fever ..................................................................................................................................... 23 3.4.1. Basic characteristics ....................................................................................................... 23 3.4.2. Prevalence of Q-fever..................................................................................................... 23 3.4.3. Works/occupations at risk............................................................................................... 24 3.5. Influenza ..................................................................................................................................... 25 3.5.1. Basic characteristics ....................................................................................................... 25 3.5.2. Prevalence of influenza................................................................................................... 25 3.5.3. Works/occupations at risk............................................................................................... 26 3.6. Avian Influenza ........................................................................................................................... 27 3.6.1. Basic characteristics ....................................................................................................... 27 3.6.2. Prevalence of avian influenza......................................................................................... 27 3.6.3. Works/occupations at risk............................................................................................... 28 3.7. SARS .......................................................................................................................................... 29 3.7.1. Basic characteristics ....................................................................................................... 29 3.7.2. Prevalence of SARS ....................................................................................................... 29 3.7.3. Works/occupations at risk............................................................................................... 29 3.8. Legionella.................................................................................................................................... 30 3.8.1. Basic characteristics ....................................................................................................... 30 3.8.2. Prevalence of Legionnaires' Disease.............................................................................. 30 3.8.3. Works/occupations at risk............................................................................................... 32 3.9. Tuberculosis................................................................................................................................ 32 3.9.1. Basic characteristics ....................................................................................................... 32 3.9.2. Prevalence of Tuberculosis............................................................................................. 33 EU-OSHA – European Agency for Safety and Health at Work (EU-OSHA) 3 Biological agents and pandemics: review of the literature and national policies 3.9.3. Works/occupations at risk ...............................................................................................35 3.10. Anthrax .....................................................................................................................................36 3.10.1. Basic characteristics........................................................................................................36 3.10.2. Prevalence of anthrax .....................................................................................................36 3.10.3. Works/occupations at risk ...............................................................................................37 3.11. Tularemia..................................................................................................................................38 3.11.1. Basic characteristics........................................................................................................38 3.11.2. Prevalence of Tularemia .................................................................................................39 3.11.3. Works/occupations at risk ...............................................................................................40 3.12. Plague ......................................................................................................................................40 3.13. Smallpox...................................................................................................................................41 3.14. Antibiotic-resistant microorganisms and health outcomes.......................................................42 3.14.1. Basic characteristics........................................................................................................42 3.14.2. Prevalence of antibiotic-resistant microorganisms..........................................................43
Load more

Recommended publications
  • Comparing National Infectious Disease Surveillance Systems: China and the Netherlands Willemijn L
    Vlieg et al. BMC Public Health (2017) 17:415 DOI 10.1186/s12889-017-4319-3 RESEARCH ARTICLE Open Access Comparing national infectious disease surveillance systems: China and the Netherlands Willemijn L. Vlieg1,2, Ewout B. Fanoy2,3*, Liselotte van Asten2, Xiaobo Liu4, Jun Yang4, Eva Pilot1, Paul Bijkerk2, Wim van der Hoek2, Thomas Krafft1†, Marianne A. van der Sande2,5† and Qi-Yong Liu4† Abstract Background: Risk assessment and early warning (RAEW) are essential components of any infectious disease surveillance system. In light of the International Health Regulations (IHR)(2005), this study compares the organisation of RAEW in China and the Netherlands. The respective approaches towards surveillance of arboviral disease and unexplained pneumonia were analysed to gain a better understanding of the RAEW mode of operation. This study may be used to explore options for further strengthening of global collaboration and timely detection and surveillance of infectious disease outbreaks. Methods: A qualitative study design was used, combining data retrieved from the literature and from semi-structured interviews with Chinese (5 national-level and 6 provincial-level) and Dutch (5 national-level) experts. Results: The results show that some differences exist such as in the use of automated electronic components of the early warning system in China (‘CIDARS’), compared to a more limited automated component in the Netherlands (‘barometer’). Moreover, RAEW units in the Netherlands focus exclusively on infectious diseases, while China has a broader ‘all hazard’ approach (including for example chemical incidents). In the Netherlands, veterinary specialists take part at the RAEW meetings, to enable a structured exchange/assessment of zoonotic signals.
    [Show full text]
  • Inclusion of Poliovirus Infection Reporting in the National Notifiable Diseases Surveillance System
    06-ID-15 Committee: Infectious Diseases Title: Inclusion of Poliovirus Infection Reporting in the National Notifiable Diseases Surveillance System Statement of the Problem In September 2005, a type 1 vaccine-derived poliovirus (VDPV) was identified in a stool specimen obtained from an Amish infant undergoing evaluation for recurrent infections, diarrhea and failure to thrive, and subsequently diagnosed as having an immune deficiency disorder (1). Hospital investigations did not find a healthcare-associated source for the infant’s infection or evidence of nosocomial transmission from the infant to other patients or healthcare workers. Investigation of the infant’s central Minnesota community identified 4 other children in 2 other households infected with the VDPV, and serologic tests indicated that 3 of the infant’s siblings had likely been recently infected with a type 1 poliovirus. Analysis of genomic sequence data from the poliovirus isolates suggested that the VDPV had been introduced into the community about 3 months before the infant was identified. Together, the data suggested that there had been circulation of the virus in the small community. Investigations in other communities in Minnesota and nearby states and Canada did not identify any additional infections and no cases of paralytic poliomyelitis were detected. Although oral poliovirus vaccine (OPV) is still widely used in most countries, IPV replaced OPV in the United States in 2000 (2). Therefore, the Minnesota VDPV infections were 1) the result of importation of a vaccine-derived poliovirus into the United States, and 2) the first documented occurrence of VDPV community transmission in a developed country (3-4). Circulating VDPVs have recently caused polio infections and outbreaks of paralytic poliomyelitis in several countries (3-5).
    [Show full text]
  • Summary of Notifiable Infectious Diseases and Conditions — United States, 2014
    Morbidity and Mortality Weekly Report Weekly / Vol. 63 / No. 54 Published October 14, 2016, for 2014 Summary of Notifiable Infectious Diseases and Conditions — United States, 2014 U.S. Department of Health and Human Services Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report CONTENTS Preface .......................................................................................................................1 Background .............................................................................................................1 Data Sources ...........................................................................................................2 Interpreting Data ...................................................................................................6 Transitions in NNDSS Data Collection ............................................................7 Method for Identifying which Nationally Notifiable Infectious Diseases and Conditions are Reportable ...................................................7 International Health Regulations ....................................................................7 Highlights for 2014 ............................................................................................ 10 PART 1 Summary of Notifiable Diseases in the United States, 2014 ............ 29 PART 2 Graphs and Maps for Selected Notifiable Diseases in the United States, 2014 ......................................................................................... 75 Selected Reading for 2014
    [Show full text]
  • Chapter 9: Monitoring, Surveillance, and Investigation of Health Threats
    Chapter 9: Monitoring, surveillance, and investigation of health threats SUMMARY POINTS · Monitoring, surveillance and investigation of health threats are vital capabilities for an effective health system. The International Health Regulations (2005) require countries to maintain an integrated, national system for public health surveillance and response, and set out the core capabilities that countries are required to achieve. · Systematic monitoring of serious infectious diseases and other conditions is typically achieved through notifiable diseases legislation based on clinical observation and laboratory confirmation. Clinical and laboratory-based surveillance also provides the basis for systematic collection of vital statistics (births, deaths, causes of death), and may extend to the reporting and analysis of risk factors for noncommunicable diseases and injuries. Systematic collection of these data informs the allocation of resources and facilitates evaluation of community-based and population-level prevention strategies. · Clinical and laboratory surveillance are passive systems that may be enhanced by sentinel surveillance and/or community-based surveillance strategies that rely on a wider range of people, including non-medical personnel. Suspected cases identified in this way must be treated with respect, protected from discrimination, with diagnosis confirmed by qualified health workers at the earliest opportunity. · A significant degree of stigma may attach to some diseases, such as HIV, sexually transmitted infections and diabetes. Notifiable diseases legislation should require the protection of personal information, and clearly define any exceptions. Concerns about discrimination and breach of privacy may be addressed by requiring certain diseases to be reported on an anonymous or de- identified basis. · In some countries, legislation or regulations may be used to establish or enhance a comprehensive public health surveillance system.
    [Show full text]
  • Infectious Diseases Infectious
    Infectious Diseases 45 Injuries Infectious Diseases Infectious diseases are caused by microorganisms, including bacteria, viruses and parasites. Some infectious diseases can spread easily through food or from person to person and can cause outbreaks that make a large number of people ill. The Georgia Department of Public Health, under the legal authority of the Official Code of Georgia Annotated (section 31-12-2), requires that health care providers report cases of specific diseases to the local health department. This section covers some of these “notifiable diseases.” DeKalb County Board of Health monitors and investigates notifiable diseases to understand trends and to prevent and control outbreaks in the county. SEXUALLY TRANSMITTED DISEASES Many infections are transmitted through sexual contact. These are commonly referred to as sexually transmitted diseases (STDs) or infections (STIs). Chlamydia, gonorrhea and syphilis are STDs that spread during unprotected vaginal, anal or oral sex. They can also pass from mother to baby in the womb or during vaginal childbirth. In DeKalb County from 2008 through 2012, there were 24,147 cases of chlamydia, 9,709 cases of gonorrhea and 872 cases of primary and secondary syphilis. (An individual with primary syphilis has no or few symptoms, while an individual with secondary syphilis has more symptoms.) As Figure 18 shows, in DeKalb County from 2008 through 2012: There were at least twice as many chlamydia cases as gonorrhea cases. The number of cases of syphilis remained consistent. Figure 18: Number of S exuall y Transmitted Disease C ases by Type and Year, DeKal b County, 2008-2012 Figure 18: Numbers of Sexually Transmitted Disease Cases by Type and Year, DeKalb County, 2008-2012 6,000 5,000 Chlamydia 4,000 Gonorrhea 3,000 Primary/Secondary 2,000 Syphilis Number of Cases 1,000 0 2008 2009 2010 2011 2012 Year Source: Sexually Transmitted Disease, Online Analytical Statistical Information System, Office of Health Indicators for Planning, Georgia Department of Public Health, 2014.
    [Show full text]
  • [SUPERSEDED] Giardiasis (August 2011)
    Alberta Health and Wellness Public Health Notifiable Disease Management Guidelines August 2011 Giardiasis Revision Dates Case Definition August 2011 Reporting Requirements August 2011 Remainder of the Guideline (i.e., Etiology to References sections inclusive) October 2005 Case Definition Confirmed Case Laboratory confirmation of infection with or without clinical illness[1]: Detection of Giardia lamblia in stool, duodenal fluid or small bowel biopsy specimen OR Detection of Giardia lamblia antigen in stool by a specific immunodiagnostic test (e.g., EIA). Probable Case Clinical illness[1] in a person who is epidemiologically linked to a confirmed case. [1] Clinical illness is characterized by diarrhea, abdominal cramps, bloating, weight loss, fatigue or malabsorption. Superseded 1 of 7 Alberta Health and Wellness Public Health Notifiable Disease Management Guidelines Giardiasis August 2011 Reporting Requirements 1. Physicians, Health Practitioners and others Physicians, health practitioners and others listed in Sections 22(1) or 22(2) of the Public Health Act shall notify the Medical Officer of Health (MOH) (or designate) of all confirmed and probable cases in the prescribed form by mail, fax or electronic transfer within 48 hours (two days). 2. Laboratories All laboratories, including regional laboratories and the Provincial Laboratory for Public Health (PLPH) shall in accordance with Section 23 of the Public Health Act, report all positive laboratory results by mail, fax or electronic transfer within 48 hours (two days) to the: Chief Medical Officer of Health (CMOH) (or designate), MOH (or designate) and Attending/ordering physician. 3. Alberta Health Services and First Nations Inuit Health The MOH (or designate) of the zone where the case currently resides shall forward the preliminary Notifiable Disease Report (NDR) of all confirmed and probable cases to the CMOH (or designate) within two weeks of notification and the final NDR (amendment) within four weeks of notification.
    [Show full text]
  • Notifiable Disease Report Form
    NOTIFIABLE DISEASE CONDITION REPORTING District Health Office Contact Information DISTRICT 1-1 / ROME / Northwest Health District DISTRICT 5-2 / MACON / North Central Health District PHONE: 706-295-6656; FAX: 706-802-5342 PHONE: 478-751-6303; FAX: 478-751-6074 www.nwgapublichealth.org EMAIL: [email protected] Counties: Bartow, Catoosa, Chattooga, Dade, Floyd, Gordon, Haralson, http://www.northcentralhealthdistrict.org/ Paulding, Polk, Walker Counties: Baldwin, Bibb, Crawford, Hancock, Houston, Jasper, Jones, Monroe, Peach, Putnam, Twiggs, Washington, Wilkinson DISTRICT 1-2 / DALTON / North Health District PHONE: 706-529-5757; FAX: 706-529-5752 DISTRICT 6 / AUGUSTA / East Central Health District EMAIL: [email protected] PHONE: 706-667-4263; FAX: 706-667-4792 http://www.nghd.org/ http://www.ecphd.com/ Counties: Cherokee, Fannin, Gilmer, Murray, Pickens, Whitfield Counties: Burke, Columbia, Emanuel, Glascock, Jefferson, Jenkins, Lincoln, McDuffie, Richmond, Screven, Taliaferro, Warren, Wilkes DISTRICT 2 / GAINESVILLE / North Health District PHONE: 770-519-7661; FAX: 770-535-5848 DISTRICT 7 / COLUMBUS / West Central Health District EMAIL: [email protected] PHONE: 706-321-6300; FAX: 706-321-6155 http://www.phdistrict2.org/ EMAIL: [email protected] Counties: Banks, Dawson, Forsyth, Franklin, Habersham, Hall, Hart, http://www.westcentralhealthdistrict.com/ Lumpkin, Rabun, Stephens, Towns, Union, White Counties: Chattahoochee, Clay, Crisp, Dooly, Harris, Macon, Muscogee, Marion, Quitman, Randolph,
    [Show full text]
  • China's Capacity to Manage Infectious Diseases
    China’s Capacity to Manage Infectious Diseases CENTER FOR STRATEGIC & Global Implications CSIS INTERNATIONAL STUDIES A Report of the CSIS Freeman Chair in China Studies 1800 K Street | Washington, DC 20006 PROJECT DIRECTOR Tel: (202) 887-0200 | Fax: (202) 775-3199 Charles W. Freeman III E-mail: [email protected] | Web: www.csis.org PROJECT EDITOR Xiaoqing Lu March 2009 ISBN 978-0-89206-580-6 CENTER FOR STRATEGIC & Ë|xHSKITCy065806zv*:+:!:+:! CSIS INTERNATIONAL STUDIES China’s Capacity to Manage Infectious Diseases Global Implications A Report of the CSIS Freeman Chair in China Studies PROJECT DIRECTOR Charles W. Freeman III PROJECT EDITOR Xiaoqing Lu March 2009 About CSIS In an era of ever-changing global opportunities and challenges, the Center for Strategic and Inter- national Studies (CSIS) provides strategic insights and practical policy solutions to decisionmak- ers. CSIS conducts research and analysis and develops policy initiatives that look into the future and anticipate change. Founded by David M. Abshire and Admiral Arleigh Burke at the height of the Cold War, CSIS was dedicated to the simple but urgent goal of finding ways for America to survive as a nation and prosper as a people. Since 1962, CSIS has grown to become one of the world’s preeminent public policy institutions. Today, CSIS is a bipartisan, nonprofit organization headquartered in Washington, D.C. More than 220 full-time staff and a large network of affiliated scholars focus their expertise on defense and security; on the world’s regions and the unique challenges inherent to them; and on the issues that know no boundary in an increasingly connected world.
    [Show full text]
  • Best Practices for the Assessment and Control of Biological Hazards Volume 2
    Best Practices for the Assessment and Control of Biological Hazards VOLUME 2 Best Practices Guidelines for Occupational Health and Safety in the Healthcare Industry CREDITS This document has been developed by the Government of Alberta, with input from: » Alberta Employment and Immigration » Alberta Health Services » Alberta Continuing Care Safety Association » The Health Sciences Association of Alberta (HSAA) » United Nurses of Alberta » Alberta Union of Provincial Employees » Alberta Home Care and Support Association » Alberta Health and Wellness COPYRIGHT AND TERMS OF USE This material, including copyright and marks under the Trade Marks Act (Canada) is owned by the Government of Alberta and protected by law. This material may be used, reproduced, stored or transmitted for non- commercial purpose. However, Crown copyright is to be acknowledged. If it is to be used, reproduced, stored or transmitted for commercial purposes written consent of the Minister is necessary. DISCLAIMER The information provided in this Guidance Document is solely for the user’s information and convenience and, while thought to be accurate and functional, it is provided without warranty of any kind. If in doubt, please refer to the current edition of the Occupational Health and Safety Act, Regulation and Code. The Crown, its agents, employees or contractors will not be liable to you for any damages, direct or indirect, arising out of your use of the information contained in this Guidance Document. This Guidance Document is current to May 2011. The law is constantly changing with new legislation, amendments to existing legislation, and decisions from the courts. It is important that you keep up with these changes and keep yourself informed of the current law.
    [Show full text]
  • Federal Register/Vol. 86, No. 15/Tuesday, January 26, 2021/Notices
    7092 Federal Register / Vol. 86, No. 15 / Tuesday, January 26, 2021 / Notices FEDERAL RESERVE SYSTEM DEPARTMENT OF HEALTH AND for Public Comments’’ or by using the HUMAN SERVICES search function. Direct written Formations of, Acquisitions by, and comments and/or suggestions regarding Mergers of Bank Holding Companies Centers for Disease Control and the items contained in this notice to the Prevention Attention: CDC Desk Officer, Office of The companies listed in this notice [30Day–21–0728] Management and Budget, 725 17th have applied to the Board for approval, Street NW, Washington, DC 20503 or by pursuant to the Bank Holding Company Agency Forms Undergoing Paperwork fax to (202) 395–5806. Provide written Act of 1956 (12 U.S.C. 1841 et seq.) Reduction Act Review comments within 30 days of notice (BHC Act), Regulation Y (12 CFR part publication. In accordance with the Paperwork 225), and all other applicable statutes Reduction Act of 1995, the Centers for Proposed Project and regulations to become a bank Disease Control and Prevention (CDC) National Notifiable Diseases holding company and/or to acquire the has submitted the information Surveillance System (NNDSS) (0920– assets or the ownership of, control of, or collection request titled National 0728, Exp. 4/30/23)—Revision—Center the power to vote shares of a bank or Notifiable Diseases Surveillance System for Surveillance, Epidemiology and bank holding company and all of the (NNDSS) to the Office of Management Laboratory Services (CSELS), Centers for banks and nonbanking companies and Budget (OMB) for review and Disease Control and Prevention (CDC). owned by the bank holding company, approval.
    [Show full text]
  • Notifiable Disease/ Condition Report Form
    NOTIFIABLE DISEASE/ CONDITION REPORT FORM All Georgia physicians, laboratories, and other health care providers are required by law to report patients with conditions of public health concern listed on the reverse of the enclosed form 3095. Both lab-confirmed and clinical diagnoses are reportable within the time intervals specified. Reporting enables appropriate public health follow-up for your patients, helps identify outbreaks, and provides a better understanding of disease trends in Georgia. For the latest information from the DHR, Division of Public Health, visit their web site at: www.health.state.ga.us District Health Office Contact Information Northwest Health District Clayton County Board of North Central Health District East Health District Epidemiology Section Health District Infectious Disease Unit Supervisor Epidemiology Unit 1305 Redmond Circle Administrative Office 811 Hemlock Street P.O. Box 15879 Bldg. 614 1380 Southlake Plaza Dr. Macon, GA 31201-2198 Savannah, GA 31416-2579 Rome, GA 30165-1391 Morrow, GA 30260-1756 Phone (478) 751-6214 Phone (912) 353-3125 Phone (706) 295-6656 Phone (770) 961-1330 FAX (478) 752-1710 FAX (912) 353-5195 FAX (706) 802-5342 FAX (770) 961-8370 East Central Health District Southeast Health District North Georgia Health District East Metro Health District 1916 North Leg Rd. Office of Infectious Disease Infectious Disease Department Epidemiology & Communicable Augusta, GA 30909-4437 1115 Church Street, Suite A 100 West Walnut Ave., Suite 92 Disease Unit Phone (706) 667-4342 Waycross, GA 31501-3525 Dalton, GA 30720-8417 324 West Pike Street FAX (706) 667-4728 Phone (912) 285-6022 (24 hr) Phone (706) 272-2342 P.O.
    [Show full text]
  • CHAPTER TEN – COMMUNICABLE DISEASE CONTROL Procedures
    CHAPTER TEN – COMMUNICABLE DISEASE CONTROL Notifiable Conditions in New Mexico Here’s the link to Notifiable Conditions in New Mexico Public Health Emergency Hotline: (505) 827- 0006 Infectious diseases occur frequently in the school setting. Factors that affect the risk of disease in schools include age of students, immunity of the group, number of students, the degree of close contact between children and providers, and the hygienic habits of students and staff. Medical events with community wide consequences occur hundreds of times each year in New Mexico, some in the school setting. Cost effective care can take on a whole new meaning when a single case of certain diseases translates into many cases, with scores of contacts needing screening, protection and surveillance. In such cases, there are substantial resources available twenty-four hours a day, seven days a week through the Epidemiology and Response Division (ERD) of New Mexico Department of Health. ERD provides expert consultation through a telephone hotline linked to health professionals experienced in management and control of outbreaks as well as laboratory assistance in making diagnoses and obtaining vaccines and/or prophylactic medications. This system is not merely a convenience; it is required by New Mexico statute and administrative code. As a part of this system, physician offices, laboratories, and other health care agencies are required to report suspected or actual cases of notifiable diseases to the Epidemiology and Response Division. Under the same statutes and rules, the Office of Epidemiology is required to identify and control outbreaks of these diseases and to report this information to the Centers for Disease Control and Prevention as a part of national data collection.
    [Show full text]